Do Valbenazine and Deutetrabenazine have the same active metabolite?

No, Valbenazine and Deutetrabenazine Do Not Have the Same Active Metabolite

Valbenazine produces only one active metabolite, [+]-α-dihydrotetrabenazine ([+]-α-HTBZ), while deutetrabenazine produces four different deuterated dihydrotetrabenazine metabolites: [+]-α-deuHTBZ, [+]-β-deuHTBZ, [-]-α-deuHTBZ, and [-]-β-deuHTBZ 1, 2, 3.

Key Metabolic Differences

Valbenazine Metabolism

• Valbenazine is metabolized primarily by carbonyl reductase to produce only [+]-α-HTBZ 2
• This single metabolite is a potent VMAT2 inhibitor (Ki ~ 3 nM) with negligible off-target receptor binding 2, 3
• The half-life of [+]-α-HTBZ is approximately 22.2 hours, allowing once-daily dosing 2, 3

Deutetrabenazine Metabolism

• Deutetrabenazine undergoes rapid ester hydrolysis and carbonyl reductase metabolism to produce four distinct deuterated HTBZ stereoisomers 1, 3
• The most abundant circulating metabolite is [-]-α-deuHTBZ (66% of total), which is a relatively weak VMAT2 inhibitor with appreciable affinity for dopamine (D2S, D3) and serotonin (5-HT1A, 5-HT2B, 5-HT7) receptors 3
• [+]-β-deuHTBZ is the most potent VMAT2 inhibitor but represents only 29% of circulating metabolites 3
• The half-life of [+]-β-deuHTBZ is approximately 7.7 hours, necessitating twice-daily dosing 1, 3

Clinical Implications

The metabolic differences translate into distinct pharmacological profiles:

• Receptor selectivity: Valbenazine's single metabolite demonstrates high VMAT2 selectivity without off-target dopamine or serotonin receptor binding, while deutetrabenazine's predominant metabolite has significant off-target activity 3, 4

• Dosing frequency: Valbenazine's longer half-life supports once-daily administration, whereas deutetrabenazine requires twice-daily dosing 1, 2, 5

• Drug interactions: Both are metabolized by CYP2D6, but valbenazine also involves CYP3A4, requiring consideration of different drug-drug interactions 1, 2, 5

While both medications are VMAT2 inhibitors approved for tardive dyskinesia and share the same mechanism of action class 6, 7, their distinct metabolic pathways and resulting active metabolites make them fundamentally different drugs with unique pharmacological characteristics.